Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 7, Number 5—October 2001
Research

Clinical Consequences and Cost of Limiting Use of Vancomycin for Perioperative Prophylaxis: Example of Coronary Artery Bypass Surgery

Giorgio Zanetti*†Comments to Author , Sue J. Goldie‡, and Richard Platt*§
Author affiliations: *Channing Laboratory, Brigham and Women's Hospital, and Eastern Massachusetts CDC Prevention Epicenter, Boston, Massachusetts, USA; †University Hospital, Lausanne, Switzerland; ‡Harvard School of Public Health, Boston, Massachusetts, USA; §Harvard Medical School and Harvard Pilgrim Health Care, Boston, Massachusetts, USA

Main Article

Table 3

Reference case analysis: quality-adjusted life expectancy and lifetime costs for a 65-year-old man undergoing coronary artery bypass graft surgery

Strategy Total costs ($) Incremental costsa ($) QALYs Incremental QALYsa Incremental cost-effectiveness ratioa
No prophylaxis 62,892 - 8.312 - -
Routine cefazolin 62,016 - 876b 8.335 0.023 Dominatedc
Routine vancomycin 61,913 - 103b 8.339 0.004 Cost saving

QALYs = quality-adjusted life years.
aRoutine cefazolin compared with no prophylaxis; routine vancomycin compared with routine cefazolin.
bNegative incremental costs represent cost savings.
cA dominant strategy is one that costs more and is less effective than an alternative strategy.

Main Article

Page created: April 26, 2012
Page updated: April 26, 2012
Page reviewed: April 26, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external